CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration—In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window-Reference-Cited by-同舟云学术

CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration—In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window

Published:2015-01-09 Issue:3 Volume:352 Page:568-578
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Villetti Gino,Carnini Chiara,Battipaglia Loredana,Preynat Laurent,Bolzoni Pier Tonino,Bassani Franco,Caruso Paola,Bergamaschi Marco,Pisano Anna Rita,Puviani Veronica,Stellari Fabio Franco,Cenacchi Valentina,Volta Roberta,Bertacche Vittorio,Mileo Valentina,Bagnacani Valentina,Moretti Elisa,Puccini Paola,Catinella Silvia,Facchinetti Fabrizio,Sala Angelo,Civelli Maurizio

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference40 articles.

1. Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases

2. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding

3. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions;Barnette;J Pharmacol Exp Ther,1998

4. Phosphodiesterase-4 Inhibitor Therapy for Lung Diseases

5. Antigen challenge of sensitized rats increases airway responsiveness to methacholine;Bellofiore;J Appl Physiol (1985),1988

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases;Journal of Medicinal Chemistry;2023-12-29

2. Optimization of M₃ Antagonist–PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD;Journal of Medicinal Chemistry;2023-08-10

3. Copper-Catalyzed Synthesis of Quinoline-4-thiols from Diaryliodonium Salts, Alkynyl Sulfides, and Nitriles;Organic Letters;2023-07-13

4. Phosphodiesterase inhibitors and lung diseases;Advances in Pharmacology;2023

5. The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation;Journal of Translational Medicine;2022-05-10